3 hrs ago
Bayer to spend $700 million making new hemophilia drugs in Germany, not Berkeley
Bayer AG will spend nearly $700 million to boost manufacturing capacity and add about 500 jobs at two German plants where it plans to make new hemophilia drugs now in Phase III clinical trials.
Trending on the Topix Network
Mon Mar 03, 2014
Week in Review: To Stage Hong Kong IPO
More detailsa . Stock Symbols: Help employers find you! Check out all the jobs and post your resume .
Fri Feb 28, 2014
The Washington Post
Bayer Raises Drug Sales Forecast as Fourth-Quarter Profit Lags
Bayer AG raised its forecast for peak sales of new drugs such as the blood thinner Xarelto even as fourth-quarter results and the revenue outlook for this year missed analyst estimates.
Thu Feb 27, 2014
Bayer Buys China's Dihon to Gain OTC and Herbal Therapies
Bayer AG agreed to buy Dihon Pharmaceutical Group Co. to gain Chinese over-the-counter products and traditional herbal treatments as drug companies expand in Asia .
Wed Feb 26, 2014
Erectile Dysfunction Drugs Market - Forecast to 2019
The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013.
Wall Street Journal
Bayer Says Bid for Algeta Successful
Bayer AG said its takeover offer for Norwegian cancer drug maker Algeta ASA was successful Wednesday, allowing Bayer to go forward with the a 1.9 billion deal to strengthen its oncology business.
Tue Feb 25, 2014
Coexistence of Trade Mercks? An expert writes ...
On Monday, in "Preliminary hearing to rule on Merck-y past", a blogpost on an interim ruling in a trade mark infringement trial before the courts of England and Wales involving the two Merck pharma companies, Merpel asked why anyone should want to use the word MERCK in the first place.
Thu Feb 20, 2014
Bayer AG Initiates Phase III Trial Of Stivarga (Regorafenib)...
Bayer AG Initiates Phase III Trial Of Stivarga Tablets In Patients With Colorectal Cancer After Resection Of Liver Metastases /PRNewswire/ -- Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying StivargaA tablets in colorectal cancer patients with resected liver metastases.
Wed Feb 19, 2014
Market Chatter- Corporate finance press digest
* France's EDF is seeking to sell 70 percent of Italian unit Edison's wind farm operations as it looks to bring on board a financial partner to help to fund expansion, three sources close to the matter said on Wednesday.
Fri Feb 14, 2014
BRIEF-Bayer says FDA rejects wider use of blood thinner Xarelto
Bayer AG : * FDA Issues Complete Response Letters for Use of XARELTO to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome * Remains committed to providing patients who have suffered from acute coronary syndrome with additional protection against stent thrombosis and secondary ... (more)